Dupixent® (dupilumab) phase 3 trial confirms significant improvements in itch and hives for patients with chronic spontaneous urticaria (csu)

Confirming the results of study a, this second pivotal trial in biologic-naÏve patients met primary and key secondary endpoints, showing treatment with dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo
REGN Ratings Summary
REGN Quant Ranking